{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:09:52Z","timestamp":1781006992229,"version":"3.54.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urolonc.2026.05.021","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:53:30Z","timestamp":1781006010000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes"],"prefix":"10.1016","author":[{"given":"Kai Wen","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jersey-Kate","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoin","family":"Douglawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert C.","family":"Ruckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhannad","family":"Alsyouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.05.021_bib0001","unstructured":"Testicular cancer \u2014 Cancer stat facts. Accessed on November 27, 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/testis.html"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.021_bib0002","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JU.0000000000000318","article-title":"Diagnosis and treatment of early stage testicular cancer: AUA guideline","volume":"202","author":"Stephenson","year":"2019","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.05.021_bib0004","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/annonc\/mdu437","article-title":"Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)","volume":"25","author":"Aparicio","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.05.021_bib0005","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/annonc\/mdv180","article-title":"A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion","volume":"26","author":"Lago-Hernandez","year":"2015","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.urolonc.2026.05.021_bib0006","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1200\/JCO.21.00637","article-title":"Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort","volume":"39","author":"Hellesnes","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.05.021_bib0007","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.6004\/jnccn.2019.7369","article-title":"Testicular cancer survivorship","volume":"17","author":"Fung","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"23","key":"10.1016\/j.urolonc.2026.05.021_bib0008","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2016.66.8822","article-title":"Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer","volume":"34","author":"Frisina","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.urolonc.2026.05.021_bib0009","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/jnci\/dji339","article-title":"Paternity following treatment for testicular cancer","volume":"97","author":"Bryd\u00f8y","year":"2005","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.021_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.19.01180","article-title":"Cardiovascular risk factors and disease after male germ cell cancer","volume":"38","author":"Lauritsen","year":"2020","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.urolonc.2026.05.021_bib0011","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer","volume":"25","author":"van den Belt-Dusebout","year":"2007","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.urolonc.2026.05.021_bib0012","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1200\/JCO.2008.19.6931","article-title":"Health-related quality of life in long-term survivors of testicular cancer","volume":"27","author":"Rossen","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.021_bib0013","doi-asserted-by":"crossref","first-page":"81","DOI":"10.6004\/jnccn.2025.7120","article-title":"Renal impairment and late toxicities comparing contemporary chemotherapy regimens for testicular cancer in a real-world setting","volume":"24","author":"Kerns","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.021_bib0014","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1634\/theoncologist.2015-0451","article-title":"Bleomycin-induced pulmonary changes on restaging computed tomography scans in two thirds of testicular cancer patients show No correlation with fibrosis markers","volume":"21","author":"den Hollander","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/mdg020","article-title":"Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours","volume":"14","author":"O'Sullivan","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.021_bib0016","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.euf.2023.01.007","article-title":"Primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors","volume":"9","author":"Alsyouf","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.021_bib0017","first-page":"504","article-title":"Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer","volume":"28","author":"Subramanian","year":"2010","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.021_bib0018","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/01.ju.0000060960.18092.54","article-title":"Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German testicular cancer Study group","volume":"169","author":"Heidenreich","year":"2003","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.05.021_bib0019","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.22.00624","article-title":"Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.021_bib0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.urology.2008.08.501","article-title":"Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer","volume":"73","author":"Pettus","year":"2009","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0021","first-page":"60","article-title":"Eleven-year experience with midline extraperitoneal retroperitoneal lymph node dissection for germ cell tumors","volume":"213","author":"Alsyouf","year":"2025","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.021_bib0022","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JU.0000000000003812","article-title":"Adjunctive surgery is often without oncological benefit at time of postchemotherapy retroperitoneal lymph node dissection","volume":"211","author":"Nestler","year":"2024","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.urolonc.2026.05.021_bib0023","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1200\/JCO.22.01822","article-title":"Primary retroperitoneal lymph node dissection for stage II seminoma: is surgery the new path forward?","volume":"41","author":"Tachibana","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.021_bib0024","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/j.clgc.2019.10.018","article-title":"Retroperitoneal lymph node dissection as primary treatment for men with testicular seminoma: utilization and survival analysis usig the National Cancer Data Base, 2004-2014","volume":"18","author":"Tabakin","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0025","article-title":"Mental health burden of a testicular cancer diagnosis: insights from a large claims database","author":"Wang","year":"2026","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.urolonc.2026.05.021_bib0026","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2005.05.061","article-title":"Study of anxiety disorder and depression in long-term survivors of testicular cancer","volume":"23","author":"Dahl","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0027","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41467-018-08170-1","article-title":"Suicide among cancer patients","volume":"10","author":"Zaorsky","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0028","article-title":"Retroperitoneal lymph node dissection in clinical stage IIA\/B metastatic seminoma: results of the COlogne trial of Retroperitoneal lymphadenectomy In metastatic seminoma (COTRIMS)","author":"Heidenreich","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","article-title":"Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA\/B (PRIMETEST)","volume":"84","author":"Hiester","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.021_bib0030","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/sj.bjc.6600771","article-title":"Radiotherapy with 16 gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group","volume":"88","author":"Classen","year":"2003","journal-title":"Br J Cancer"},{"issue":"33","key":"10.1016\/j.urolonc.2026.05.021_bib0031","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1200\/JCO.2007.15.9103","article-title":"Chemotherapy As an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish germ cell cancer group study","volume":"26","author":"Garcia-del-Muro","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0032","article-title":"Diagnosis and treatment of early-stage testicular cancer: AUA Guideline Amendment 2023","author":"Stephenson","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0033","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/JU.0000000000000792","article-title":"Long-term oncologic outcomes after primary retroperitoneal lymph node dissection: minimizing the need for adjuvant chemotherapy","volume":"204","author":"Douglawi","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0034","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2022.12.010","article-title":"How much chemotherapy is required to optimise long-term outcomes in clinical stage 2 seminoma?","volume":"84","author":"Sigg","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000003697","article-title":"Primary retroperitoneal lymph node dissection for Seminoma metastatic to the retroperitoneum","volume":"211","author":"Matulewicz","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/S0302-2838(23)00794-7","article-title":"A0753 - Outcomes of minimally invasive retroperitoneal lymph node dissection (Primary MI- RPLND) followed by adjuvant carboplatin (AUC7) for clinical stage IIa\/b seminoma","volume":"83","author":"Cazzaniga","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.021_bib0037","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.eururo.2016.05.031","article-title":"Enhanced recovery pathways versus standard care after cystectomy: a meta-analysis of the effect on perioperative outcomes","volume":"70","author":"Tyson","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0038","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0022-5347(05)64837-9","article-title":"Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection","volume":"168","author":"Chang","year":"2002","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.021_bib0039","first-page":"305","article-title":"Improving postoperative quality of care in germ cell tumor patients: does scheduled alvimopan, acetaminophen, and gabapentin improve short-term clinical outcomes after retroperitoneal lymph node dissection?","volume":"38","author":"Calaway","year":"2020","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.021_bib0040","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.eururo.2017.02.024","article-title":"Midline extraperitoneal approach to retroperitoneal lymph node dissection in testicular cancer: minimizing surgical morbidity","volume":"72","author":"Syan-Bhanvadia","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.021_bib0041","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.urology.2012.07.006","article-title":"Midline extraperitoneal approach for retroperitoneal lymph node dissection for testicular germ cell tumor","volume":"80","author":"Kim","year":"2012","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0042","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bju.15986","article-title":"Robot-assisted retroperitoneal lymph node dissection: a systematic review of perioperative outcomes","volume":"132","author":"Garg","year":"2023","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89823-y","article-title":"Indications, feasibility and outcome of robotic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours","volume":"11","author":"Ohlmann","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.021_bib0044","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2025.0018","article-title":"NCCN Guidelines\u00ae insights: testicular Cancer, version 2.2025","volume":"23","author":"Gilligan","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.021_bib0045","article-title":"Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: a multicenter collaborative study","volume":"41","author":"Ghoreifi","year":"2023","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.021_bib0046","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.euo.2019.01.014","article-title":"Robotic postchemotherapy retroperitoneal lymph node dissection for testicular cancer","volume":"4","author":"Li","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0047","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00345-021-03832-0","article-title":"A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections","volume":"40","author":"Lloyd","year":"2022","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.021_bib0048","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2016.03.031","article-title":"Robot-assisted laparoscopic retroperitoneal lymph node dissection for testicular cancer: evolution of the technique","volume":"70","author":"Stepanian","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.021_bib0049","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.eururo.2016.05.017","article-title":"Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer","volume":"71","author":"Pearce","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.021_bib0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.eururo.2019.05.031","article-title":"Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer","volume":"76","author":"Calaway","year":"2019","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.05.021_bib0051","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S1470-2045(22)00564-2","article-title":"Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01\/10): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Papachristofilou","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.021_bib0052","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.eururo.2022.04.031","article-title":"The GETUG SEMITEP trial: de-escalating chemotherapy in good-prognosis seminoma based on fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"82","author":"Loriot","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.021_bib0053","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2004.07.188","article-title":"2-18fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial","volume":"22","author":"De Santis","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0054","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mdr052","article-title":"2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial","volume":"23","author":"Bachner","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0055","article-title":"Radiotherapy vs observation for post chemotherapy residual mass in advanced seminoma","author":"Murthy","year":"2025","journal-title":"ClinicalTrials.gov identifier"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.021_bib0056","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00432-020-03429-x","article-title":"Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin","volume":"147","author":"Belge","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0057","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.2047-2927.2014.00269.x","article-title":"MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker","volume":"3","author":"Spiekermann","year":"2015","journal-title":"Andrology"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.021_bib0058","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.molonc.2013.08.002","article-title":"Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle","volume":"7","author":"Gillis","year":"2013","journal-title":"Mol Oncol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.05.021_bib0059","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.08.004","article-title":"MicroRNA as a liquid biomarker to detect malignancy in small testicular masses","author":"Chavarriaga","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.021_bib0061","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euo.2020.11.004","article-title":"Utility of serum miR-371a-3p in predicting relapse on surveillance in patients with clinical stage I testicular germ cell cancer","volume":"4","author":"Lobo","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.021_bib0062","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41416-021-01643-z","article-title":"Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours","volume":"126","author":"Fankhauser","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0063","article-title":"A systematic review of pN0 testicular seminoma: a new clinical entity and future directions","author":"Farkouh","year":"2023","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0064","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.juro.2018.02.068","article-title":"Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor","volume":"200","author":"Le\u00e3o","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.021_bib0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2020.10.024","article-title":"Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors","volume":"79","author":"Nappi","year":"2021","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.05.021_bib0066","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.celrep.2018.05.039","article-title":"Integrated molecular characterization of testicular germ cell tumors","volume":"23","author":"Shen","year":"2018","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.021_bib0067","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/JU.0000000000004164","article-title":"miR-371a-3p predicting viable tumor in patients undergoing retroperitoneal lymph node dissection for metastatic testicular cancer: the SWENOTECA-MIR study","volume":"212","author":"Thor","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0068","article-title":"A prospective observational cohort study to assess MiRNA 371 for outcome prediction in patients with newly diagnosed germ cell tumors","author":"Nichols","year":"2025","journal-title":"ClinicalTrials.gov identifier"},{"issue":"14","key":"10.1016\/j.urolonc.2026.05.021_bib0069","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1200\/JCO.22.02002","article-title":"Plasma micro-RNA 371 expression in early-stage germ cell tumors: are we ready to move toward biology-based decision making?","volume":"41","author":"Alsyouf","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.05.021_bib0070","article-title":"Longitudinal evaluation of circulating tumor DNA as a prognostic biomarker to detect molecular residual disease in germ cell tumors","volume":"9","author":"Hassoun","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.021_bib0071","doi-asserted-by":"crossref","DOI":"10.1111\/bju.16926","article-title":"Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer","volume":"136","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.021_bib0072","first-page":"307","article-title":"Testis cancer care in North Carolina: implications for real-world evidence and cancer surveillance","volume":"20","author":"McMahon","year":"2022","journal-title":"Clin Genitourin Can"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.021_bib0073","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.21037\/tau-22-855","article-title":"Novel approaches to redesign surveillance strategies following orchiectomy for localized testicular cancer: a narrative review","volume":"12","author":"Matulewicz","year":"2023","journal-title":"Transl Androl Urol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.05.021_bib0074","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.396","article-title":"WATChmAN: a randomized trial of virtual surveillance versus standard in-person care for clinical stage I testicular cancer","volume":"38","author":"Hamilton","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2026.05.021_bib0075","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1200\/JCO.21.01199","article-title":"Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, phase III, noninferiority trial (TRISST)","volume":"40","author":"Joffe","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:53:40Z","timestamp":1781006020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":75,"alternative-id":["S1078143926005405"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.021","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}